AnaptysBio (NASDAQ:ANAB) CFO Dennis Mulroy Sells 1,908 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 1,908 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total value of $86,069.88. Following the sale, the chief financial officer owned 17,667 shares of the company’s stock, valued at $796,958.37. This trade represents a 9.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Dennis Mulroy also recently made the following trade(s):

• On Monday, January 5th, Dennis Mulroy sold 3,363 shares of AnaptysBio stock. The stock was sold at an average price of $43.26, for a total transaction of $145,483.38.
• On Monday, December 22nd, Dennis Mulroy sold 10,000 shares of AnaptysBio stock. The shares were sold at an average price of $50.00, for a total transaction of $500,000.00.
• On Tuesday, December 16th, Dennis Mulroy sold 15,725 shares of AnaptysBio stock. The stock was sold at an average price of $44.85, for a total transaction of $705,266.25.

AnaptysBio Trading Down 3.1%

Shares of ANAB opened at $43.80 on Friday. The stock’s 50 day moving average is $42.46 and its two-hundred day moving average is $31.30. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $52.47. The firm has a market capitalization of $1.21 billion, a PE ratio of -15.53 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. The business had revenue of $76.32 million during the quarter, compared to analysts’ expectations of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%. On average, sell-side analysts predict that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its Board of Directors has authorized a stock repurchase program on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.

Key Headlines Impacting AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded AnaptysBio to a “strong‑buy,” which can drive retail and institutional buying interest and lift short‑term momentum. UBS upgrade / coverage note
• Positive Sentiment: AnaptysBio filed a partial motion to dismiss Tesaro/GSK’s anticipatory‑breach claim related to Jemperli royalties; a successful dismissal would reduce legal and royalty exposure and improve free‑cash‑flow prospects tied to that program. AnaptysBio seeks partial dismissal in GSK dispute
• Negative Sentiment: CEO Daniel Faga sold about $662k of stock (9,202 shares), a disclosed insider sale that can raise investor concerns about insider conviction even though his remaining stake is still large. CEO stock sale article
• Negative Sentiment: Other insiders (CFO Dennis Mulroy, Paul Lizzul, Eric Loumeau and others) also sold shares in the same filing period — several sizable dispositions that increase selling pressure and may temper the upside from analyst upgrades or legal wins. SEC Form 4 filings detail these trades. SEC Form 4 filings (insider sales)

Wall Street Analysts Forecast Growth

Several research firms recently commented on ANAB. Stifel Nicolaus decreased their price objective on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Wells Fargo & Company increased their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Wedbush reissued an “outperform” rating and set a $50.00 price objective on shares of AnaptysBio in a research note on Monday, November 24th. Wall Street Zen raised AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Finally, Barclays lowered their target price on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, AnaptysBio currently has a consensus rating of “Moderate Buy” and an average price target of $60.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its holdings in shares of AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 473 shares in the last quarter. Bessemer Group Inc. grew its stake in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,377 shares during the last quarter. Osaic Holdings Inc. increased its stake in AnaptysBio by 11,630.0% during the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 2,326 shares during the last quarter. Finally, Covestor Ltd raised its stake in AnaptysBio by 131,540.0% during the third quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 6,577 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.